Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27045973 | 0.79 | NPC1 (0.32) | NPC1RAB9A | |
| SCHEMBL1830663 | 0.71 | L3MBTL1 (0.32) | — | |
| SCHEMBL1604058 | 0.71 | L3MBTL1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL29571133 | 0.70 | L3MBTL1 (0.31) | — | |
| Water SCHEMBL1831822 | 0.70 | L3MBTL1 (0.31) | — | |
| SCHEMBL19691749 | 0.70 | CBFB (0.49) | NPC1RAB9ACYP1A2KDM4EMAPT | |
| SCHEMBL6866475 | 0.70 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL672597 | 0.69 | NOTUM (0.42) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28856174 | 0.69 | CCR1 (0.47) | KDM4E | |
| SCHEMBL10558227 | 0.68 | ALDH1A1 (0.43) | NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025027051-A1 | SPHINGOSINE-1-PHOSPHATE LYASE INHIBITORS FOR USE IN THE TREAMENT OF NEURODEGENERATIVE DISEASES | AB SCIENCE (FR) | 2025-02-06 | — | — | WO | claimed |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | claimed |
| WO-2025027051-A1 | SPHINGOSINE-1-PHOSPHATE LYASE INHIBITORS FOR USE IN THE TREAMENT OF NEURODEGENERATIVE DISEASES | AB SCIENCE (FR) | 2025-02-06 | — | — | WO | disclosed |
| EP-4017844-B1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | AC BIOSCIENCE SA (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-4017844-B1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | AC BIOSCIENCE SA (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | AC BIOSCIENCE (CH) | 2023-12-26 | — | — | US | disclosed |
| US-20230121797-A1 | A COMBINATION OF FLAVONOIDS AND SPHINGOSINE 1 PHOSPHATE LYASE INHIBITORS FOR THE TREATMENT OF LUNG INFLAMMATION | AUCLAIR, CHRISTIAN (FR) | 2023-04-20 | — | — | US | disclosed |
| US-20220306587-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | AC BIOSCIENCE SA (CH) | 2022-09-29 | — | — | US | disclosed |
| CN-114555567-A | Compounds and their use for the treatment of infectious diseases and cancer | AC生命科学有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021032857-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | AC BIOSCIENCE SA (CH) | 2021-02-25 | — | — | WO | disclosed |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | disclosed |
| US-8653126-B2 | Imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653126-B2 | Imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653126-B2 | Imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| EP-2537831-A1 | IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-26 | — | — | EP | disclosed |
| EP-2537831-A1 | IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-20120316170-A1 | Imidazole Derivative | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120316170-A1 | Imidazole Derivative | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120316170-A1 | Imidazole Derivative | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
| WO-2011102404-A1 | IMIDAZOLE DERIVATIVE | 第一三共株式会社 (JP) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850234-B2 | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | SPHK1, S1PR1, S1PR2 | NPC1 1609/4885RAB9A 3176/4885CYP1A2 4495/4885 |
| US-20220306587-A1 | COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER | SGPL1, SPHK1, S1PR1 | NPC1 152/4885RAB9A 3546/4885CYP1A2 2539/4885 |
| US-20230121797-A1 | A COMBINATION OF FLAVONOIDS AND SPHINGOSINE 1 PHOSPHATE LYASE INHIBITORS FOR THE TREATMENT OF LUNG INFLAMMATION | SGPL1, SPHK1, S1PR1 | NPC1 368/4885RAB9A 2666/4885CYP1A2 2399/4885 |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | SPHK1, S1PR1, S1PR2 | NPC1 1609/4885RAB9A 3176/4885CYP1A2 4495/4885 |
| US-20120316170-A1 | Imidazole Derivative | S1PR2, S1PR1, SPHK2 | NPC1 149/4885RAB9A 2274/4885CYP1A2 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.